By Colin Kellaher


Gilead Sciences Inc. on Thursday said long-time pharmaceutical development and manufacturing executive Taiyin Yang plans to retire after nearly three decades with the biopharmaceutical company.

Gilead said Stacey Ma, currently executive vice president and head of technical operations at Sana Biotechnology Inc., will succeed Dr. Yang as executive vice president of pharmaceutical development and manufacturing, effective July 18.

The Foster City, Calif., company said Dr. Ma will become a member of its senior leadership team and report to Chairman and Chief Executive Daniel O'Day.

Dr. Yang, who joined Gilead in 1993, became senior vice president of pharmaceutical development and manufacturing in 2005 and executive vice president in 2015, with responsibility for all of the company's investigational compounds and marketed products.

Gilead developed the world's first HIV single-tablet regimen under Dr. Yang's leadership and advanced more than 25 compounds from early-stage development to market.


Write to Colin Kellaher at colin.kellaher@wsj.com


(END) Dow Jones Newswires

06-02-22 0941ET